BIOMAT Database Logo BIOMAT Database Logo

Treatment of nephrotic hyperlipidemia with lovastatin. 1991

M Elisaf, and M Dardamanis, and M Pappas, and G Sferopoulos, and K C Siamopoulos

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D008148 Lovastatin A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver. Lovastatin, 1 alpha-Isomer,Mevinolin,6-Methylcompactin,Lovastatin, (1 alpha(S*))-Isomer,MK-803,Mevacor,Monacolin K,1 alpha-Isomer Lovastatin,6 Methylcompactin,Lovastatin, 1 alpha Isomer,MK 803,MK803,alpha-Isomer Lovastatin, 1
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009404 Nephrotic Syndrome A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction. Childhood Idiopathic Nephrotic Syndrome,Frequently Relapsing Nephrotic Syndrome,Multi-Drug Resistant Nephrotic Syndrome,Pediatric Idiopathic Nephrotic Syndrome,Steroid-Dependent Nephrotic Syndrome,Steroid-Resistant Nephrotic Syndrome,Steroid-Sensitive Nephrotic Syndrome,Multi Drug Resistant Nephrotic Syndrome,Nephrotic Syndrome, Steroid-Dependent,Nephrotic Syndrome, Steroid-Resistant,Nephrotic Syndrome, Steroid-Sensitive,Nephrotic Syndromes,Steroid Dependent Nephrotic Syndrome,Steroid Resistant Nephrotic Syndrome,Steroid Sensitive Nephrotic Syndrome,Steroid-Dependent Nephrotic Syndromes,Steroid-Resistant Nephrotic Syndromes,Steroid-Sensitive Nephrotic Syndromes,Syndrome, Nephrotic,Syndrome, Steroid-Sensitive Nephrotic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M Elisaf, and M Dardamanis, and M Pappas, and G Sferopoulos, and K C Siamopoulos
Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
June 1988, Kidney international,
M Elisaf, and M Dardamanis, and M Pappas, and G Sferopoulos, and K C Siamopoulos
Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria.
April 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation,
M Elisaf, and M Dardamanis, and M Pappas, and G Sferopoulos, and K C Siamopoulos
Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil +/- lovastatin.
June 1993, The American journal of cardiology,
M Elisaf, and M Dardamanis, and M Pappas, and G Sferopoulos, and K C Siamopoulos
Remission of nephrotic syndrome on lovastatin treatment.
January 1994, Nephron,
M Elisaf, and M Dardamanis, and M Pappas, and G Sferopoulos, and K C Siamopoulos
Management of primary mixed hyperlipidemia with lovastatin.
June 1990, Archives of internal medicine,
M Elisaf, and M Dardamanis, and M Pappas, and G Sferopoulos, and K C Siamopoulos
Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study.
January 1990, Cardiology,
M Elisaf, and M Dardamanis, and M Pappas, and G Sferopoulos, and K C Siamopoulos
Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
January 1993, Clinical therapeutics,
M Elisaf, and M Dardamanis, and M Pappas, and G Sferopoulos, and K C Siamopoulos
Lovastatin and nephrotic syndrome.
April 1991, Southern medical journal,
M Elisaf, and M Dardamanis, and M Pappas, and G Sferopoulos, and K C Siamopoulos
Lovastatin treatment of hyperlipidemia in kidney transplant recipients on cyclosporine immunosuppression.
October 1994, Transplantation proceedings,
M Elisaf, and M Dardamanis, and M Pappas, and G Sferopoulos, and K C Siamopoulos
Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome.
July 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Copied contents to your clipboard!